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 What’s already known about this topic? 
• In psoriasis the non-lesional skin already contains abnormalities as base for the 
manifestation of the disease.  
• Fibronectin and its splice variant EDA+FN are essential extracellular matrix 
proteins influencing major cellular processes and they are abnormally expressed 
in psoriatic skin. 
• KGF is overexpressed in psoriatic lesional skin and contribute to keratinocyte 
hyperproliferation. 
 
What does this study add? 
• KGF and its receptor, FGFR2 is overexpressed in the psoriatic non-lesional skin. 
• KGF in an autocrine manner influences the regulation EDA+FN production in 
fibroblasts through MEK1 signaling. 
• Fibroblasts express the FGFR2-IIIc splice variant of FGFR2 receptor. 
• STAT1 negatively regulates FN and EDA+FN production in normal cultured 
fibroblasts, but not in fibroblasts, derived from psoriatic non-lesional skin.  
• STAT1 is active in healthy skin and psoriatic lesional skin, but not in non-lesional 
psoriatic skin. 
 
  
Summary 
Background Data indicate that in psoriasis abnormalities are already present in the non-
lesional skin. TGFβ, KGF together with fibronectin and α5β1 integrin was suggested to play a 
crucial role in the pathogenesis of psoriasis by influencing inflammation and keratinocyte 
hyperproliferation. 
Objectives To investigate the expression of KGF, FGFR2, fibronectin (FN) and EDA+FN in 
healthy and non-lesional psoriatic skin and to study the effect of KGF on the regulation of FN 
and EDA+FN production by fibroblasts. 
Methods Healthy, non-lesional psoriatic skin and lesional psoriatic skin were 
immmunostained for α5 integrin, KGF, FGFR2, EDA+FN and STAT1. KGF treated cell 
cultures were analyzed for FN and EDA+FN mRNA and protein by real-time RT-PCR and 
flow cytometry respectively. The four major downstream signaling of KGF was investigated 
by blocking experiments using MEK1, AKT1/2, STAT1 and STAT3 inhibitors.  
Results The expression of α5 integrin, EDA+FN, KGF and its receptor FGFR2 is elevated in 
psoriatic non-lesional skin compared to healthy skin. KGF mildly induced EDA+FN, but not 
FN expression in healthy fibroblasts through MAPK signaling. Fibroblasts express the 
FGFR2-IIIc. STAT1 negatively regulates both FN and EDA+FN expressions in healthy 
fibroblasts and this regulation is compromised in fibroblasts derived from non-lesional 
psoriatic dermis. We detected active STAT1 in healthy and lesional skin, similar to a previous 
report, however, in the non-lesional skin STAT1 activation was absent in tissues far away 
from lesions.  
Conclusions The production of FN, EDA+FN by fibroblasts and the signaling of STAT1 is 
abnormally regulated in the psoriatic non-lesional skin.  
  
Introduction 
 
It is well stated that psoriasis is an inflammatory skin disease in which both innate and 
adaptive immune activation play an essential role in the maintenance of the abnormal skin 
phenotype 1. However, it is less known how much resident cells of the tissue contribute to the 
pathology. A reasonable approach to seek for alterations in tissue responses in psoriasis is to 
investigate the phenotypically normal looking non-lesional (NL) psoriatic skin. The main 
fibronectin receptor α5β1 integrin was found to be overexpressed in the NL psoriatic epidermis 
relative to normal 2,3. There is evidence that proper regulation of integrin expression in 
keratinocytes is essential for normal epidermal homeostasis as shown by the suprabasal 
overexpression of integrins in transgenic mice resulting in epidermal hyperproliferation and 
inflammatory reaction4. In the steady state of normal human adult epidermis α5 integrin 
expression of keratinocytes is downregulated. A possible explanation of α5 integrin 
overexpression in NL skin is the presence of fibronectin (FN) and one of its isoforms, the 
extra-domain-A containing fibronectin (EDA+FN), in the microenvironment of basal 
keratinocytes 3,5. Keratinocyte growth factor (KGF/FGF7) is a member of the fibroblast 
growth factor (FGF) family produced by mesenchymal cells and considered to be a major 
growth factor for keratinocytes. Several reports suggest that KGF reduces the ability of 
keratinocytes to initiate terminal differentiation and undergo programmed cell death. 
Overexpression of KGF in the basal epidermal cell layer of transgenic mice results in 
epidermal hyperplasia6. There is also evidence suggesting that fibroblasts from L and NL skin 
of psoriatic patients induce keratinocyte outgrowth by producing soluble signals7. More 
recently, it has been reported that KGF can induce the expression of α5 integrin and delays the 
expression of keratin 10 and transglutaminase in keratinocytes8. Indirect evidence, such as 
measurement of mitogenic activity, suggests that the specific receptor for KGF on epithelial 
cells is the IIIb splice variant of fibroblast growth factor receptor 2 (FGFR2)9. 
According to our observations, psoriatic NL skin displays a marked overexpression of KGF, 
FGFR2, α5 integrin and EDA+FN compared to healthy skin, therefore in this study we focused 
on investigating regulatory mechanisms involving KGF and fibronectin. Our results revealed 
that KGF regulate EDA+FN production in an autocrine manner through MAPK signaling in 
healthy fibroblasts. With these results we designed an in silico model to predict a possible 
regulatory network for the effect of KGF on EDA+FN production. We provide in vitro 
evidence that both FN and EDA+FN are negatively regulated by activated STAT1 in healthy 
fibroblasts, and this is in contrast to psoriatic NL skin-derived fibroblasts. Active, 
phosphorylated STAT1 was found in healthy skin as well as in psoriatic lesions, but not in 
psoriatic NL skin, suggesting a crucial mechanism for keeping NL skin in a preactivated state 
for developing a chronic wound healing phenotype. 
  
Materials and methods 
 Skin biopsies 
Patients with moderate-to-severe chronic plaque type psoriasis and healthy volunteers (age 
18-60 years) were enrolled into the study. Patients had a medication-free period of at least 4 
weeks of systemic and/or at least 2 weeks without local therapy. Participant informed consent 
was obtained prior surgical intervention. PASI score was determined for all patients by 
dermatologists. Samples were collected from 16 patients and 25 healthy volunteers for the 
experiments. Mechanical stress was induced by tape stripping procedure, and then punch 
biopsies were taken from uninvolved skin of psoriatic patients (n=6) and from healthy (n=6) 
subjects from tape stripped and non-treated (control) skin area from the buttock area at 24 and 
48 hours after treatment (supplementary figure 1) for all other experiments tissues without the 
introduction of mechanical stress were used. All tissue collection complied with the 
Guidelines of the Helsinki Declaration and was approved by the Regional and Institutional 
Research Ethics Committee (2799, 3517).  
 
Immunofluorescent staining  
Human punch biopsies were frozen embedded, stored at -80 °C, then cut into 6 µm sections. 
Samples were fixed in Fixation/Permeabilization Concentrate and Diluent (eBioscience, San 
Diego, CA) and resuspended in PBS. The sections were incubated for 30 min in goat serum 
(Sigma-Aldrich, St. Louis, MO, USA). The following primary antibodies were used: FGFR2 
(1:100, Bek (C-17), Santa Cruz Biotechnology, Santa Cruz, CA), KGF (1:500, FGF-7 (N-14), 
Santa Cruz Biotechnology), α5 integrin (1:200, Becton-Dickinson, Franklin Lakes, NJ, USA), 
EDA+FN (1:500, clone IST9, Abcam, Cambridge, UK), and p-STAT1(Ser727), p-STAT1 
(Tyr701), (both 1:400, Cell Signaling Technology, Beverly, MA) overnight at 4°C. Goat anti-
rabbit IgG-Alexa Fluor 488, donkey anti-goat IgG-Alexa Fluor 546, goat anti-mouse IgG-
Alexa Fluor 647 and Alexa Fluor 546 were used as secondary antibodies (all 1:500, from Life 
Technologies, Carlsbad, CA) for 2 h, at room temperature. Sections were incubated without 
the primary antibody or with isotype control antibody for negative staining controls. Nuclei 
were stained with DAPI (Sigma-Aldrich). 
Cultured human fibroblasts, keratinocytes and HaCaT cells were collected after brief 
trypsinization (0.25% trypsin solution, Sigma Aldrich) and centrifuged onto a slide using a 
cytocentrifuge (Cytopro™, Wescor, Logan, UT, USA), then fixed in 2% paraformaldehyde 
(Sigma-Aldrich). Stainings were carried out, as described above. Images were documented 
with a Zeiss AxioImager Z1 fluorescence microscope (Carl Zeiss Microscopy GmbH, 
Munich, Germany) equipped with an AxioCam MRm camera. Image processing and data 
analysis were conducted using ZEN 2012 Microscope and Imaging or ImageJ software. 
 
Flow cytometry 
Cells were harvested as described, above fixed in Fixation/Permeabilization Concentrate and 
Diluent (eBioscience) and resuspended in PBS. Primary antibodies anti-EDA+FN (1:500, 
clone IST9, Abcam), anti-FN (1:1000, clone IST4, Sigma-Aldrich) were applied for 45 min. 
Mouse IgG1 isotype antibody (Sigma-Aldrich) was used, for negative as control. Cells were 
then washed in PBS, and incubated with secondary antibodies as described above. Samples 
were analysed on a FACS Calibur flow cytometer equipped with 488 and 633 nm lasers 
(Becton–Dickinson). 
 
Statistical analysis 
For statistical analysis, Repeated Measures Friedman ANOVA, Wilcoxon or one-way 
ANOVA were used.	 Multiple comparisons were done with SigmaPlot software (Systat 
Software, Inc., Chicago, IL, USA). A probability test was used to test for normality, P≤0.05 
was considered significant. 
 
Detailed information of the materials and methods regarding cell culture experiments, RT 
qRT-PCRs and the description of the in silico model are presented as supplement 
(Supplementary materials and methods). 
 
 
  
Results 
Altered protein expression of α5 integrin, EDA+FN, KGF and FGFR2 in psoriatic non-
lesional skin 
Healthy skin and psoriatic NL skin were investigated for differences in the expressions of α5 
integrin, EDA+FN, KGF and FGFR2 before and 24, 48 hours after tape stripping. 
Immunofluorescent staining revealed a striking difference in all protein expressions examined 
even without tape stripping between normal and psoriatic non-lesional skin (Fig. 1). Mild 
mechanical stress introduced by tape stripping of the skin did not lead to any obvious changes 
in α5 integrin, EDA+FN, KGF and FGFR2 expressions or distributions at 24 and 48 hours 
after treatment in NL skin. In healthy control sections a slight increase in all protein 
expression was observed based on immunostaining (Fig. S1a-d; see Supporting Information).  
 
KGF treatment of healthy human fibroblasts leads to the elevation of EDA+FN 
production  
EDA+FN and KGF are known to stimulate keratinocyte proliferation. KGF induces the 
expression of the major FN cell surface receptor α5β1 integrin. Given the differences in 
EDA+FN and KGF protein levels in healthy and NL psoriatic skin, we set out to investigate a 
putative regulatory connection between these two molecules. Exogenous treatment of cultured 
healthy fibroblasts with KGF for 24 hours increased the level of the EDA+FN splice variant, 
but not the total FN protein based on immunostaining and flow cytometry measurements (Fig. 
2a, b). A similar increase in the EDA+FN mRNA splice variant was detected, while the total 
FN mRNA remained unchanged (Fig. 2c).  We also investigated this effect of KGF on normal 
human keratinocytes and melanocytes and on the keratinocyte cell line, HaCaT. As expected, 
keratinocytes and HaCaT cells expressed the FN and the EDA+FN at a very low level 
compared to fibroblasts, while melanocytes expressed both proteins at a comparable level to 
fibroblasts (Fig. S3). However, upon in vitro KGF treatment these cells did not display 
detectable changes in mRNA and protein expressions of EDA+FN and total FN (Fig. S2a-c; 
see Supporting Information).  
 
 
Expression of FGFR2 splice variants in fibroblasts, melanocytes and keratinocytes 
Two splice variants have been identified for FGFR2 designated as FGFR2-IIIb and FGFR2-
IIIc that have different ligand binding preferences. These result were based on mitotic activity 
measurements16. KGF has been shown to act on the FGFR2-IIIb variant increasing cellular 
proliferation17. We determined the expression of the splice variants on healthy fibroblasts, 
melanocytes and keratinocytes using specific primers designed for RT-PCR, revealing that 
melanocytes and keratinocytes expressed the FGFR2-IIIb only, while fibroblasts mainly 
expressed the FGFR2-IIIc variant (Fig. 3a, b). 
 
MAPK signaling is involved in the regulation of EDA+FN by KGF in healthy fibroblasts 
FGF signals (including KGF) are coordinated by four major pathways: the RAS-RAF-MAPK, 
the PI3-AKT, the STAT and the PLCγ signaling18,19. In order to get a better insight into the 
modulation of FN expression by KGF in cultured fibroblasts derived from healthy skin, we 
performed blocking experiments targeting key molecules of the signal transduction pathways 
using specific inhibitors available for MEK1 (MAPK), Akt1/2 (PI3-Akt), STAT1 and STAT3 
(STAT) either alone or in combination. After 24h of inhibitory treatment the expressions of 
FN and EDA+FN was determined by flow cytometry and RT-PCR. The KGF induced 
EDA+FN elevation was abolished by the inhibition of MEK1 and returned to the level of 
control fibroblasts (Fig. 4a). In contrast, blocking Akt1/2 did not have an effect on EDA+FN 
protein expression (Fig. S4; see Supporting Information). The inhibition of STAT1 or STAT3 
did not influence KGF-mediated changes in EDA+FN levels (Fig. 4b), however, impairing 
these signaling molecules resulted in a KGF independent elevation of both FN and EDA+FN 
protein levels that was significant in the case of STAT1 inhibition (Fig. 4c).  
 
Abnormal STAT1 activation in psoriatic skin plays a role in the regulation of both FN 
and EDA+FN 
To investigate further, we compared the FN and EDA+FN expressions between healthy and 
psoriatic NL skin derived fibroblasts 24 hours after STAT1 or STAT3 inhibition in culture. 
Changes upon STAT3 impairment were not significant, however, blockade of STAT1 did not 
lead to the elevation of total FN and the EDA+FN splice variant in fibroblasts from NL skin in 
contrast to healthy controls (Fig. 4c). Therefore, we investigated the phosphorylation pattern 
of STAT1 at Tyr701 and Ser727 positions that are known to be key amino acid modifications 
leading to dimerization and influencing activity. Immunofluorescent staining for the 
phosphorylated Ser727 was highest in lesional psoriatic skin, lower, but clearly detectable in 
healthy skin whereas NL skin samples showed the lowest intensity. In two out of four 
investigated NL samples phosphorylation was undetectable (Fig. 4d). Staining for the 
phosphorylated Tyr701 showed a much less noticeable but similar pattern. In samples of 
patients where no serine phosphorylation was detected in the NL skin, the staining for the 
phosphorylated Tyr701 was also not visible in either NL or L areas. To elucidate whether 
differences observed in STAT1 activity among patients correlated with the severity of the 
disease, PASI scores of donor patients were compared. The patients whose NL skin was 
negative for phosphorylations of STAT1 had a lower PASI score (12.4 and 17.8), therefore 
we were able to take NL samples further away from lesions at least 10 cm distance whereas 
patients with detectable, but low STAT1 activity in NL skin had a higher PASI score (19.6 
and 20). 
 
In silico model construction 
We constructed an in silico model based on our in vitro results involving KGF- and FN-
signaling and the resultant transcriptional regulation network (Fig. 5, Table S1-2). Our data 
already suggested the participation of MAPK signaling in KGF induced fibronectin splicing. 
The generated co-expression matrix implied a potential role of peptidyl-prolyl cis–trans 
isomerase (PPIG), a protein important in both protein folding and splicing20, which is 
regulated by MEK1 induced AP-1. Changes in MEK1 activity could lead to the modulation of 
fibronectin splicing through PPIG resulting in elevated EDA+FN level. Our model also 
indicated that STAT3 negatively regulates the expression of MEK1. This suggested inhibitory 
effect of STAT3 on MEK1 may account for the increased EDA+FN production upon STAT 
inhibition. However, our model did not explain our data on the significant increase in 
EDA+FN and FN following STAT1 inhibition in normal fibroblasts. The schematic summary 
model of KGF induced changes on fibronectin based on our results (in vivo, in vitro and in 
silico) of normal skin is presented in Figure 6. 
 
 
 
Discussion 
One of the major characteristics of psoriatic lesional skin is the hyperproliferation of 
keratinocytes, where KGF is known to play an important role. At the protein level both KGF 
and FGFR2 were demonstrated to be elevated in lesional skin compared to normal skin21. At 
the mRNA level in non-lesional as well as in lesional tissue an increased expression for both 
KGF and FGFR2 transcripts were also described by others21,22. KGF stimulates keratinocyte 
proliferation and it influences terminal differentiation6,23. The only known source of KGF in 
the skin are fibroblasts, and keratinocytes can mediate KGF production in fibroblasts through 
IL-124,25, establishing a double paracrine regulatory loop, controlled by AP-1 subunits c-Jun 
and JunB, and directing the regeneration of the epidermis and maintaining tissue homeostasis 
in the skin26. It was reported that micro RNA miR-125 is downregulated in psoriatic lesional 
tissue. miR-125 is known to have a negative influence on keratinocyte proliferation, partially 
by downregulating FGFR2 expression and driving keratinocytes towards differentiation27.  
Integrins and their corresponding extracellular ligands also influence cell proliferation and 
differentiation 28. Overexpression of α5 integrin and EDA+FN has already been reported in 
connection with psoriasis and our group demonstrated that one of the potential sources of 
EDA+FN in the NL psoriatic skin are activated keratinocytes 29. Another report on NL skin 
has showed that EDA+FN was localized mainly at the epidermal-dermal junction 5. It is well 
established that α5 integrin and EDA+FN could play an important regulatory role in the 
abnormal epidermal homeostasis of psoriatic skin3,29, and more recent evidence suggests that 
EDA+FN could be crucial in activating immune cells30,31. The EDA motif encompasses two 
non-classical binding sites for α4β1 and α9β1 integrins32, receptors present on the surface of T-
cells33,34 that could enhance T cell migration and accumulation in EDA+FN containing 
tissues, such as the skin.  
EDA+FN promotes acute inflammation and brain injury following cerebral ischemia in 
mice35. EDA+FN is normally absent in human plasma, however patients with chronic 
inflammation and ischemic stroke have high plasma EDA+FN. The abnormally regulated 
overproduction of EDA+FN in psoriatic fibroblasts may be responsible not only for 
maintaining a local chronic inflammation in the skin, but by influencing plasma levels that 
could play a role in the systemic inflammation that is reported recently in psoriasis36.  The 
EDA+FN rich extracellular milieu in the psoriatic skin could be crucial for maintaining the 
characteristic epidermal changes, as well as the chronic inflammation in psoriatic lesions (for 
review see37,38).  
It has been reported that KGF stimulates EDA inclusion in a mouse mammary epithelial cell 
line (SCp2)39. Although, the exact regulation of EDA+FN splicing is not completely clear, it is 
known that TGF-β enhances EDA+FN production40. Our in silico model on KGF and FN 
signaling corroborate our experimental results in suggesting the participation of MEK1 in 
KGF induced fibronectin splicing through peptidyl-prolyl cis–trans isomerase (PPIG), a 
protein known to be important in protein folding and splicing20 and regulated by MEK1 
induced AP-1.  
Autocrine feedback of several different FGFs through FGFRs exists under both normal and 
pathological conditions16,19,41. KGF exerts its effect mainly through FGFR2-IIIb, but also via 
FGFR2-IIIc and FGFR117. Since both FGFR2 and FGFR1 can initiate MEK1 signaling, KGF 
could potentially modulate fibronectin splicing in a similar autocrine manner as other FGFs, 
most likely either through FGFR2-IIIc or FGFR116,42 in fibroblasts. However the 
participation other unknown receptors also cannot be excluded and further research is needed 
to understand the exact mechanism through which KGF affects FN splicing. Directly blocking 
EDA+FN seems less feasible as a therapeutic approach, as blocking KGF or its receptors 43.  
 
STAT1 is the founding member of the STAT (signal transducer and activator of transcription) 
family and it is activated by interferons (IFNs), and signaling from IL-27, IL-35 and TLRs 44. 
There is ample evidence implicating IFNγ in the pathomechanism of psoriasis45. Aberrant 
signaling and transcription have been reported for psoriatic keratinocytes with regard to 
SOCS1, a negative regulator of IFNγ signaling46, and also for STAT1 and IRF-1 (interferon 
regulated factor 1)47. The complex role of STAT1 in immune regulation is apparent from 
animal studies showing that both STAT1-/- and IFNγ-/- mice are highly susceptible to 
experimental autoimmune encephalomyelitis (EAE)48,49. It has been demonstrated that in 
both multiple sclerosis (MS) and in the EAE model α5 integrin and FN could be responsible 
for the extensive vascular remodelling, characteristic for MS, that takes place during the 
presymptomatic phase in EAE50. The regulatory connection between STAT1 and FN 
described in this paper may explain the more severe disease manifestation in STAT-/- animals. 
STAT1 has diverse functions, it inhibits certain genes and it is a functional transcription factor 
even in the absence of inducer-mediated activation. Among its major targets of negative 
regulation are genes encoding proteins involved in regulating the extracellular matrix: matrix 
metalloproteinases (MMPs), perlecan, bullosus phemphigoid antigen-1 (BPAG1) 51. As our 
results indicate, in normal homeostatic skin tissue a steady state of STAT1 activation is 
present and this could be partially responsible for downregulating FN and EDA+FN 
production, since blocking STAT1 in normal fibroblasts results in enhanced production of FN 
and EDA+FN. The absent suppressive function of STAT1 in psoriatic fibroblasts could be 
crucial in the pathomechanism of psoriasis. Using a STAT1 decoy oligodeoxynucleotide 
(dODN)-containing ointment Wagner et al. were able to inhibit hapten-induced contact 
hypersensitivity reaction in animal models, indicating that topical STAT1 blockade could be a 
novel anti-inflammatory therapy in skin inflammation52. Our data indicate that in psoriasis 
STAT1 inactivation characterizes the uninvolved skin, thus, this type of therapy may well 
work as a symptomatic therapy for the lesional skin. 
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Figure legend 
 
 
 
Figure 1. Increased expression of α5 integrin, EDA+FN, KGF and FGFR2 in non-lesional 
skin without mechanical stress stimuli. Immunofluorescent analysis of α5 integrin, 
EDA+FN, KGF and FGFR2 in healthy (upper row) and non-lesional skin (lower row) (n=6). 
Bar: 50 µm 
 
 
 
Figure 2. The expression of EDA+FN is induced by KGF in normal human fibroblasts. 
KGF treated fibroblasts and the change in expression in FN and EDA+FN at 24 hours. a) 
Immunofluorescent detection of EDA+FN. b) Flow cytometry measurement of EDA+FN and 
FN levels following KGF treatment. RFI: relative fluorescence intensity. c) FN or EDA+FN 
mRNA expression following KGF stimulation. Values are expressed in arbitrary units. Data 
represent the mean±SEM (n=6). Bar: 50 µm. 
 
Figure 3. Human fibroblasts in culture mainly express the FGFR2-IIIc while 
melanocytes and keratinocytes the FGFR2-IIIb splice variant of FGFR2.                         
a) RT-PCR products specific for FGFR2-IIIb and –IIIc were run on a 2% agarose gel of 
cultured human fibroblasts (FB), melanocytes (MC) and keratinocytes (KC). b) FGFR2 
mRNA expression by fibroblasts for the two investigated splice variants detected by real-time 
RT-PCR. Values are expressed in arbitrary units. 
 
 
Figure 4. KGF influenced elevation of the EDA+FN is mediated through MAPK 
signaling and altered STAT1 regulation of EDA+FN and FN expression in psoriasis. a) 
FN and EDA+FN levels of healthy fibroblasts treated with KGF alone or in combination with 
MEK1 inhibitor. b) Following treatment of healthy fibroblasts with KGF alone or in 
combination with inhibitors for STAT1, STAT3 or both. c) The effect of STAT1 and STAT3 
inhibition on FN and EDA+FN in healthy and non-lesional skin derived fibroblasts. d) 
Immunofluorescent analysis of STAT1 Ser727 phosphorylation. H: healthy, NL: non-lesional, 
and L: lesional skin. Data represent the mean±SEM (n=6). RFI: relative fluorescence 
intensity. Bar: 50 µm. 
 
 
Figure 5. In silico model of KGF and FN signaling. Green arrow: positive transcriptional 
regulation; Red arrow with circle arrowhead: negative transcriptional regulation; Arrows with 
dashed lines: undetermined direction of regulation. 
 
 
Figure 6. Schematic model of investigated molecules playing a role in KGF mediated 
EDA+FN production in healthy skin.  
  
 
Supplementary materials and methods 
 
Cell culture 
Primary keratinocytes, melanocytes and fibroblasts were obtained from healthy participants or 
psoriatic patients by enzymatic digestion of skin biopsies according to a standard protocol. 
Briefly skin specimens were first washed in Salsol A solution (Human Rt, Gödöllő, Hungary) 
supplemented with 2% antibiotic/antimycotic solution (Sigma-Aldrich). Skin samples were 
then cut into narrow strips and incubated in Dispase solution (Roche Diagnostics, Mannheim, 
Germany) overnight at 4°C.  The epidermis was subsequently separated from the dermis and 
incubated in 0.25% trypsin/0.02% EDTA (PAA, Pasching, Austria) for 5 min at 37°C to 
achieve a single-cell epidermal suspension. Fibroblasts were obtained by incubating the 
dermis in Digestion Mix (Collagenase, Hyaluronidase and Deoxyribonuclease) for 2h at 37°C. 
The cell suspensions were filtered through a 100 µm nylon mesh (BD Falcon, San Jose, CA, 
USA) and pelleted by centrifugation. 
Fibroblasts were grown in low glucose DMEM medium containing 5% FBS. Melanocytes 
were maintained in Mel-mix medium as previously described 10. Keratinocytes were grown in 
keratinocyte serum-free medium (Gibco® Keratinocyte SFM Kit; Life Technologies, 
Copenhagen, Denmark). HaCaT cells were kindly provided by Prof N.E. Fusenig and cultured 
in high-glucose DMEM medium containing 10% FBS. All media was supplemented with 1% 
antibiotic/antimycotic (PAA) and 1% L-glutamine solution (PAA). Fibroblasts, keratinocytes, 
melanocytes, and HaCaT cells were cultured at 37°C and 5% CO2 in humidified conditions. 
Depending on the cell growth, the medium was changed every 2–4 days and cells were 
passaged at 80% confluence. In our experiments, fibroblasts at passage number 5, 
keratinocytes and melanocytes at passage 3 were used at 70% confluence.  
Fibroblasts, keratinocytes and HaCaT cells were cultured in 6-well plates at a starting density 
of 200,000 cells/well and incubated with 25 ng/mL KGF (ProSpec -Tany TechnoGene Ltd., 
Rehovot, Israel) for 24 h; untreated cells were used as controls. For KGF signaling pathway 
blocking experiments the following inhibitors were used: MEK1 inhibitor (PD98059, 20µM), 
Akt ½ kinase inhibitor (10µM), STAT1 inhibitor (Epigallocatechin gallate, 40µM) and 
STAT3 inhibitor (Stattic, 4µM), all provided by Sigma-Aldrich, concentrations were applied	as 
previously described 11-13. 
RNA extraction and real-time quantitative reverse transcription polymerase chain 
reaction (RT qRT-PCR)  
For RNA isolation fibroblasts, melanocytes and keratinocytes were	 cultured as described 
above. Cells on 6 well plates were washed once with PBS, then harvested with 0.5 ml 
TRIzolTM Reagent (Life Technologies). Total RNA was isolated according to the 
manufacturer`s instructions. RNA concentration was determined from A260 values. All RNA 
was treated with DNA-free™ reagents (Life Technologies). cDNA was synthesized from 1 µg 
total RNA with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA)	
according to the manufacturer’s protocol.	 
For EDA+FN qPCR amplification iQTM Supermix (from Bio-Rad Laboratories Hercules, CA, 
USA) was used. The EDA+FN primers were constructed as described previously 14. The 
amplification protocol for EDA+FN qPCR was the following: 95°C for 3 min, and then 95°C 
for 15 s and 56°C for 30 s, repeated 40 times.  
FN1 and 18S amplifications were carried out with FastStart TaqMan Probe Mastermix (Roche 
Basel, Switzerland) using the following primers: FN1 forward	 5’-
GGAAAGTGTCCCTATCTCTGATACC-3’, reverse 5’-AATGTTGGTGAATCGCAGGT-
3’, probe: #33. 18S RNA forward 5’-CTCAACACGGGAAACCTCAC-3’, reverse 5’-
CGCTCCACCAACTAAGAACG-3’, probe: #77 (probes were from the Roche Universal 
Probe Library). Primers were designed using Probefinder for the Universal Probe Library 
system (Roche Diagnostics, Basel, Switzerland). FN1 and 18SrRNA amplifications were 
carried out under the following conditions: 95°C for 3 min, and then 95°C for 15 s and 57°C 
for 1 min, repeated 40 times.  
For FGFR2-IIIb and FGFR2-IIIc, specific custom TaqMan primer/probe sets (Life 
Technologies, Carlsbad, CA, USA) were developed	 as described previously 15 and for 
amplification the following protocol was used: 95°C for 10 min, and then 95°C for 15 s and 
60°C for 1 min, repeated 40 times.  
RT-PCR experiments were carried out on the LightCycler® 480 System Real-Time PCR 
machine (Roche Cobas Z 480 Roche Diagnostics). The abundance of each gene products was 
normalized to the 18S rRNA gene expression in each examined sample. Relative mRNA 
levels were calculated by the 2-ΔΔCt method. Data are expressed as arbitrary units proportional 
to the mRNA level. 
Bioinformatics analysis and model construction 
STRING, KEGG database and Reactome were used as a source to create protein-protein 
interactions and signaling pathways; SABiosciences’ transcription factor binding site data and 
CisRED (p<0.001) were applied for modeling protein-DNA interactions. Direction of 
transcriptional regulation was assessed with expression correlation matrix. Data of a 
microarray study with 48 dermal fibroblast samples carried out by Gabig-Cimińska et al. was 
downloaded from Gene Expression Omnibus. Probe with the largest interquartile range (IQR) 
was selected for genes with multiple probes. Coexpressional matrix was constructed using 
MATLAB R2014b (MathWorks Inc., Natick, MA). The genes and proteins related to KGF 
signaling, fibronectin-signaling, splicing and the regulation of these genes were collected 
(summarized in Supplementary Table 1.) and used for filtered matrix construction 
(Supplementary Table 2.). We used Pearson correlation coefficients with p values under 0.05 
for the assessment of the direction of transcriptional regulation. If correlation coefficient was 
positive it was considered an upregulation, and if it was negative, down regulation was 
defined. 
 Supplementary figure 1. Mild mechanical stress induced by tape stripping has no effect 
on the expression of α5 integrin, EDA+FN, KGF or FGFR2 in non-lesional psoriatic skin 
and only a mild effect on healthy skin. The protein expression of α5 integrin (a), EDA+FN 
(b), KGF (c) and FGFR2 (d) was visualized by immunofluorescent staining 24 and 48 hours 
following tape stripping in healthy and in non-lesional skin. Bar: 50 µm. 
 
 
 Supplementary figure 2. Exogenous KGF treatment has no effect on EDA+FN 
expression of keratinocytes and HaCaT cells.  The expression of EDA+FN was visualized 
by immunostaining (a), its protein amount was quantified by flow cytometry (b) and mRNA 
expression was determined by real-time RT-PCR measurements (c) following 24 hours of 25 
ng/ml KGF treatment of healthy human keratinocytes and HaCaT cells. RFI: relative 
fluorescence intensity. Values are expressed in arbitrary units.  Bar: 50 µm. 
 
  
Supplementary figure 3. Fibroblast and melanocytes show higher expression of EDA+FN 
and FN than keratinocytes. The expression of EDA+FN and FN was compared among 
healthy fibroblasts, melanocytes and keratinocytes by flow cytometry 24 hours following 
plating measured by flow cytometry. MFI: mean fluorescence intensity. 
 
 
 
 Supplementary figure 4. Exogenous KGF treatment triggered increase of EDA+FN and 
FN is not influenced by Akt1/2 inhibition. The level of fibroblasts produced EDA+FN and 
FN was measured by flow cytometry following 24h of KGF incubation with or without 
Akt1/2 inhibitor. Cells untreated with KGF or treated alone with the Akt1/2 inhibitor were 
used as controls. RFI: relative fluorescence intensity. 
 
Supplementary Table 1. List of genes applied for the construction of the co-expression 
matrix gene model. 
Supplementary Table 2. Co-expression matrix of genes in our model Red bold characters 
indicate correlation coefficients with p<0.05 between transcription factors and known targets. 
Red-shaded cells show positive correlation, blue shaded cells show negative correlation. 
Shade marks with the strength of correlation. Cells with thick margin means that there is 
binding site of the given transcription factor in the promoter region of the target gene. 
 
